A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients.

The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumor cells.

Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated.

Researchers have discovered how a protein "master regulator" goes awry, leading to metastasis, the fatal step of cancer.

Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov Consumer Inquiries: